logo
PSU stocks still attractive: MOSL lists top long-term bets including SBI, HAL, BEL

PSU stocks still attractive: MOSL lists top long-term bets including SBI, HAL, BEL

Mint3 days ago

Indian public sector undertakings (PSUs) have experienced a remarkable revival in recent years, with Motilal Oswal Financial Services (MOSL) spotlighting their long-term potential in a detailed report. While FY25 brought in some normalization after a stellar post-COVID run, MOSL says the foundational strength of PSU businesses remains intact. The brokerage believes select PSUs across banking, defence, and energy sectors remain well-positioned to generate wealth over the next several years. 'Our top PSU ideas are SBI, HAL, BEL, PowerGrid and Coal India,' said MOSL in its latest note.
MOSL highlighted that PSUs delivered a compounded annual profit growth (PAT CAGR) of 36 percent during FY20–25—higher than the 30 percent reported by India Inc overall and far ahead of the private sector's 26 percent. This robust profit performance contributed to a 32 percent CAGR in the BSE PSU Index during the same period, significantly outpacing the Nifty50's 19 percent CAGR.
'FY25 did witness some moderation,' MOSL acknowledged, noting that overall PSU profits dipped 2 percent YoY, primarily due to weak performance in the Oil & Gas (O&G) sector. Excluding O&G, PSU profits rose 16 percent in FY25, following a strong 23 percent jump in FY24.
BFSI, particularly PSU banks, was the key driver of profit growth in FY25, with PSU banks clocking a 26 percent increase. O&G, by contrast, declined 44 percent. 'This divergence illustrates the need to be selective in PSU exposure,' MOSL said, underlining that strength persists in sectors with structural tailwinds such as financial services, defence, and infrastructure.
Importantly, the report shows that the PSU contribution to India Inc's overall profit pool surged to 37.5 percent in FY25—up from just 29 percent a year ago and only 18 percent in FY20. 'The turnaround in PSU profitability is structural, not cyclical,' MOSL asserted.
Valuations for PSU stocks have moderated since their peak. The BSE PSU Index's market cap hit ₹ 74 lakh crore in July 2024, then declined to ₹ 51 lakh crore in February 2025 amid a broader correction, before rebounding to ₹ 64 lakh crore in June. The current market cap stands 14 percent below its all-time high, providing room for upside, according to MOSL.
The BSE PSU Index now trades at a P/E of 11.7x, down from 13.8x in July 2024 and up from 9.8x in February 2025, suggesting more reasonable valuations.
The PSU Index delivered a 10 percent CAGR over the last decade (June 2015–June 2025), underperforming the Nifty50's 12 percent CAGR. However, most gains came in the second half of the decade. The index contracted 9 percent between 2015–2020, but rebounded with a strong 32 percent CAGR from 2020 to 2025.
Notably, the share of loss-making PSUs in the overall profit pool fell dramatically—from 45 percent in FY18 to just 1 percent in FY25. 'The PSU basket is no longer dragged by chronic underperformers,' said MOSL, noting a meaningful transformation in efficiency and governance.
Looking ahead, MOSL expects a 10 percent PAT CAGR for its PSU coverage universe over FY25–27. This growth will be led by BFSI (53 percent contribution to incremental profits), followed by O&G (20 percent), and Metals (12 percent).
Strategically, MOSL is bullish on select PSUs that benefit from policy tailwinds, Make-in-India initiatives, and infrastructure push. SBI remains a top pick due to robust credit growth and stable asset quality. HAL and BEL are favoured for their role in defence indigenization, while PowerGrid benefits from power transmission investments. Coal India also finds favour due to its consistent cash generation and role in India's energy security.
Overall, while FY25 marked a normalization phase for PSU stocks after an extraordinary post-pandemic rally, MOSL believes the long-term story remains compelling. 'With solid fundamentals, improving governance, and favourable policy tailwinds, PSUs deserve a spot in long-term investor portfolios,' the brokerage said. The transformation of Indian PSUs from inefficient state behemoths to efficient, growth-oriented enterprises is well underway—and investors who spot the structural shifts early could be handsomely rewarded.
Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Ketan Kumar Joshi named J&K Bank CFO for 3-year term, replaces Fayaz Ganai
Ketan Kumar Joshi named J&K Bank CFO for 3-year term, replaces Fayaz Ganai

Business Standard

timean hour ago

  • Business Standard

Ketan Kumar Joshi named J&K Bank CFO for 3-year term, replaces Fayaz Ganai

The Bank notified the appointment to the stock exchanges in accordance with Sebi Regulations Press Trust of India Srinagar The Jammu and Kashmir Bank on Sunday announced the appointment of Ketan Kumar Joshi as its new chief financial officer for a term of three years. Joshi has replaced Fayaz Ahmad Ganai, a spokesperson of the J&K Bank said. The Bank notified the appointment to the stock exchanges in accordance with Sebi Regulations. "A seasoned professional in banking and finance, Joshi brings over two decades of extensive experience across Indian and international financial institutions," the spokesperson said. Before joining the J&K Bank, Joshi served as CFO at North East Small Finance Bank Ltd. (2019-2024), where he successfully led a number of critical initiatives. He also spearheaded the bank's system migration from FIS (PROFILE) to BSG (TURING), ensuring capital growth aligned with business expansion and regulatory requirements. Joshi has served in Afghanistan with Maiwand Bank, Bakhtar Bank, and Ghazanfar Bank. He also served as senior vice president at Bank of Tokyo-Mitsubishi UFJ Ltd, Mumbai. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Contribute to stable borders: Chinese President Xi urges residents of Tibetan village bordering Arunachal Pradesh
Contribute to stable borders: Chinese President Xi urges residents of Tibetan village bordering Arunachal Pradesh

Time of India

timean hour ago

  • Time of India

Contribute to stable borders: Chinese President Xi urges residents of Tibetan village bordering Arunachal Pradesh

Beijing: Chinese President Xi Jinping on Sunday called on the Tibetan residents of a village situated near the Indian border to contribute towards fostering prosperity and stability in the border areas. "Learning that the village has undergone new changes in recent years and villagers' incomes have increased, I feel happy for you," Xi replied to a letter received from residents of Nyingchi, a prefecture-level area located close to the Arunachal Pradesh border. China claims Arunachal Pradesh as part of South Tibet, which is firmly rejected by India. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Memperdagangkan CFD Emas dengan salah satu spread terendah? IC Markets Mendaftar Undo Xi visited Nyingchi in 2021, becoming the only Chinese president to have visited the border areas of Tibet. Xi, in his letter, voiced hope that Nyingchi residents will, under the guidance of the Communist Party's policies to develop border areas and improve people's lives, do an even better job in protecting the natural beauty of the plateau region, developing the village's tourist brand, and contributing to building a prosperous and stable border area. Live Events In recent years, China has built a number of villages along the Tibetan border areas to ensure border security and development. In his letter, Xi also urged the people in the Tibet Autonomous Region to uphold ethnic solidarity and create a happier and better life, the state-run Xinhua news agency reported. During his 2021 visit to Nyingchi, Xi visited the Nyang River Bridge to inspect the ecological preservation in the basin of the Brahmaputra River , which is called Yarlung Zangbo in the Tibetan language. Last year, China approved the construction of the world's largest dam, stated to be the planet's biggest infrastructure project, costing USD 137 billion, on the Brahmaputra river in Tibet, which has raised concerns in the riparian states of India and Bangladesh.

Torrent Pharma to acquire controlling stake in JB Chemicals from KKR
Torrent Pharma to acquire controlling stake in JB Chemicals from KKR

Mint

timean hour ago

  • Mint

Torrent Pharma to acquire controlling stake in JB Chemicals from KKR

Ahmedabad-based drugmaker Torrent Pharmaceuticals is set to acquire a controlling stake in JB Chemicals and Pharmaceuticals (JB Pharma) from global investment firm KKR, at an equity valuation of ₹25,689 crore. The deal will be followed by a merger of the two entities, the company announced on Sunday evening. The deal will strengthen Torrent's presence in the Indian market, as well as facilitate its entry into the fast-growing contract development and manufacturing (CDMO) segment. Torrent will acquire a 46.39% equity stake (on a fully diluted basis) in JB Pharma through a share purchase agreement for ₹11,917 crore at ₹1,600 per share, followed by a mandatory open offer to acquire up to 26% of the company's shares from public shareholders, at an open offer price of ₹1,639.18 per share. Torrent also intends to acquire up to 2.80% of equity shares from certain employees of JB Pharma at the same share price as KKR, the company said in a release. The investment in JB Pharma yielded an over 5x return for KKR with a gross internal rate of return of about 36%, a person aware of the development, who did not wish to be quoted, told Mint. KKR has had a strong track record of healthcare investments in India, including a $600 million financing to Manipal Group recently and a 5x return on its investment in Max Healthcare in 2022. The acquisition will be followed by a merger between Torrent and JB Pharma through a scheme of arrangement. JB Pharma's shares rose 2.3% to ₹1,792.20 apiece, while those of Torrent Pharma settled 4.7% higher at ₹3,375 on the NSE on Friday. The acquisition will provide Torrent access to a fast-growing India franchise, with JB's leading brands in the chronic segment, and entry into untapped therapeutic areas like ophthalmology, strengthen Torrent's market share in the Indian market, and facilitate its entry into the CDMO segment. It will also aid consolidation in key international markets, the company said. 'Torrent's deep India presence and JB Pharma's fast growing India business, combined with the CDMO and international footprint, offers immense potential to scale both revenue and profitability," Samir Mehta, executive chairman, Torrent Pharmaceuticals, said in the statement. 'Moreover, the CDMO platform provides a new long-term avenue of growth for Torrent," he added. Torrent Pharma was engaged in prolonged talks to acquire KKR's stake in JB Pharma last year. The deal, however, fell through over valuation concerns. KKR acquired a 54% stake in JB Pharma from the promoters, the Mody family, in July 2020 for about ₹3,100 crore, or ₹745 per share. The investment firm sold over 5% of stake in the company in March 2025 through block deals for ₹1,459 crore, bringing its holding down to 47.84%. Torrent Pharmaceuticals has grown over the years through inorganic moves. In 2017, it acquired women's healthcare brands from Novartis, as well as Unichem's Indian branded business along with its Sikkim plant. In 2022, it acquired Curatio Healthcare for ₹2,000 crore. In an interview with the Economic Times earlier this month, Torrent's managing director-designate Aman Mehta said the company is aiming to be one of the top three pharma companies in the Indian market in the next three to five years. JB Pharma is one of the fastest growing pharma companies in India, and comes with flagship brands such as Cilacar, Metrogyl, Nicardia and Rantac. The company also exports its finished formulations to over 40 countries, including the US, and is a leading CDMO player in the segment of medicated lozenges. JB Pharma recorded revenue of ₹3,918 crore in FY24-25, growing 12% year-on-year. Of this, its revenue from the domestic market was ₹2,269 crore, growing 20% YoY. 'Over the past five years, JB Pharma has emerged as one of India's fastest growing pharmaceutical players, owing to KKR's strategic guidance, stewardship of our independent directors and a focused strategic and executional excellence by the management team. We have built a strong foundation to deliver market-leading growth as well as consistent improvement in profitability in the medium and long term," said Nikhil Chopra, chief executive officer and whole time director of JB Pharma.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store